By Carlo Martuscelli

Bayer AG (BAYN.XE) said Thursday that it is investing up to $100 million to research new treatments for cardiovascular and gynecological diseases with U.S. biotech Dewpoint Therapeutics.

The two companies signed an option, research and license agreement, Bayer said. Under the terms of the deal it will use Dewpoint's biomolecular condensates platform to drive research into the disease areas.

Germany's Bayer also said that it will have the option to exclusively license new therapy candidates developed from the research activities.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

November 14, 2019 08:47 ET (13:47 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Bayer.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Bayer.